154 related articles for article (PubMed ID: 33625082)
1. Towards Optimizing Risk-adapted Treatment of APML in ATRA/ATO Era: How Can Prediction of Early Mortality Help?
Buhtoiarov IN
J Pediatr Hematol Oncol; 2021 May; 43(4):158. PubMed ID: 33625082
[No Abstract] [Full Text] [Related]
2. [Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations].
Creutzig U; Dworzak M; von Neuhoff N; Rasche M; Reinhardt D
Klin Padiatr; 2018 Oct; 230(6):299-304. PubMed ID: 30399642
[TBL] [Abstract][Full Text] [Related]
3. Microgranular variant of acute promyelocytic leukemia with cytoplasmic projections resembling micromegakaryocytes.
Jiang W; Lee SH
Blood; 2018 Nov; 132(21):2314. PubMed ID: 30467190
[No Abstract] [Full Text] [Related]
4. The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.
Chen X; Hong Y; Zheng P; You X; Feng J; Huang Z; Wang Y
Cancer; 2020 Jan; 126(2):311-321. PubMed ID: 31714584
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
6. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
7. First report of successful management of acute promyelocytic leukemia in a pregnant female with All-Trans-Retinoic Acid and Arsenic Trioxide-based induction regimen.
Khosla H; Jain A; Tatawadiya S; Prasad P; Nagpal K; Chaudhry S; Sharma M; Gupta DK; Saluja S; Jain A
Blood Cells Mol Dis; 2020 Nov; 85():102476. PubMed ID: 32688220
[No Abstract] [Full Text] [Related]
8. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of acute promyelocytic leukemia in pregnancy with single-agent all-trans retinoic acid.
Nellessen CM; Janzen V; Mayer K; Giovannini G; Gembruch U; Brossart P; Merz WM
Arch Gynecol Obstet; 2018 Feb; 297(2):281-284. PubMed ID: 29110117
[TBL] [Abstract][Full Text] [Related]
10. Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.
Russell N; Burnett A; Hills R; Betteridge S; Dennis M; Jovanovic J; Dillon R; Grimwade D;
Blood; 2018 Sep; 132(13):1452-1454. PubMed ID: 30097508
[No Abstract] [Full Text] [Related]
11. Flexural Eruption Associated With Arsenic Trioxide Therapy in a Patient With Acute Promyelocytic Leukemia.
Teran VA; Wilson BB; Guffey DJ
JAMA Dermatol; 2019 Mar; 155(3):389-391. PubMed ID: 30673070
[No Abstract] [Full Text] [Related]
12. [Therapies for newly diagnosed acute promyelocytic leukemia].
Yokoyama Y
Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
[TBL] [Abstract][Full Text] [Related]
13. Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia.
Kennedy GA; Marlton P; Cobcroft R; Gill D
Br J Haematol; 2000 Dec; 111(4):1103-5. PubMed ID: 11167746
[TBL] [Abstract][Full Text] [Related]
14. A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic.
Pemmaraju N
Cancer; 2021 Aug; 127(16):2867-2869. PubMed ID: 33891316
[No Abstract] [Full Text] [Related]
15. The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia.
Zhu HH; Guo ZP; Jia JS; Jiang Q; Jiang H; Huang XJ
Leuk Res; 2018 Feb; 65():14-19. PubMed ID: 29232592
[TBL] [Abstract][Full Text] [Related]
16. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.
Tallman M; Lo-Coco F; Barnes G; Kruse M; Wildner R; Martin M; Mueller U; Tang B
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):771-7. PubMed ID: 26361645
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
19. Acute promyelocytic leukaemia presenting as necrotising fasciitis of the perineum (Fournier gangrene).
Furtado VF; Batalini F; Staziaki PV; Prilutskiy A; Sloan JM
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567203
[TBL] [Abstract][Full Text] [Related]
20. [Acute promyelocytic leukaemia].
Tøstesen M; Østergård LSG; Kjeldsen E; Stentoft J; Nørgaard JM
Ugeskr Laeger; 2018 Jan; 180(3):. PubMed ID: 29336301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
